Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Bradley Corr to Neoplasm Recurrence, Local

This is a "connection" page, showing publications Bradley Corr has written about Neoplasm Recurrence, Local.

 
Connection Strength
 
 
 
0.926
 
  1. Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019 06; 153(3):517-520.
    View in: PubMed
    Score: 0.418
  2. Gonzalez Bosquet J, Polio A, George E, Tarhini AA, Cosgrove CM, Huang MS, Corr B, Leiser AL, Salhia B, Darcy K, Tarney CM, Dood RL, Dockery LE, Edge SB, Cavnar MJ, Landrum L, Rounbehler RJ, Churchman M, Wagner VM. Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence. JCO Precis Oncol. 2025 May; 9:e2400859.
    View in: PubMed
    Score: 0.160
  3. Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
    View in: PubMed
    Score: 0.157
  4. Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barqu?n A, G?lvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio P?rez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. The efficacy and safety of mirvetuximab soravtansine in FRa-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2025 Mar; 36(3):321-330.
    View in: PubMed
    Score: 0.155
  5. Whelan K, Dillon M, Strickland KC, Pothuri B, Bae-Jump V, Borden LE, Thaker PH, Haight P, Arend RC, Ko E, Jackson AL, Corr BR, Ayoola-Adeola M, Wright JD, Podwika S, Smitherman C, Thomas S, Lightfoot M, Newton M, Washington C, Mullen M, Cosgrove C, Harsono AAH, Powell K, Herzog TJ, Salani R, Alvarez Secord A. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. Gynecol Oncol. 2023 11; 178:44-53.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)